M&A funding spikes as AstraZeneca lands $7bn sub-curve
AstraZeneca, the UK drug company, showed the eager demand for merger and acquisition financings this week when it achieved ultra-tight pricing on a $7bn bond issue to fund its acquisition of US biotech firm Alexion Pharmaceuticals.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: